G390 – Supervision of chemotherapy, biologic agent, or bispecific antibody infusion
OHIP Diagnostic & Therapeutic Procedures Code — DIAGNOSTIC AND THERAPEUTIC PROCEDURES · Schedule of Benefits
Supervision of chemotherapy for induction phase of acute leukemia or myeloablative therapy prior to bone marrow transplantation (maximum of 1 per induction phase or myeloablative therapy); and/or supervision of biologic agent(s) such as Chimeric Antigen Receptor T-Cell Therapy (CAR-T) infusion (maximum of 1 per infusion); and/or supervision of bispecific antibody infusion, during initial dosing phase, where there is a high risk of cytokine release syndrome (maximum of 3 per initial dosing phase)
When to Use
- Use G390 for the supervision of a CAR-T cell infusion, which is distinct from the routine chemotherapy supervision covered by G382.
- Apply this code during the initial dosing phase of bispecific antibody therapy specifically when the clinical focus is the management of high-risk cytokine release syndrome.
- Bill G390 for the supervision of myeloablative conditioning regimens immediately preceding a bone marrow transplant, rather than standard maintenance chemotherapy.
Common Pitfalls
- Billing G390 more than once for a single CAR-T infusion or more than three times for a bispecific antibody initial dosing phase will trigger an automatic rejection.
- Using G390 for routine chemotherapy supervision that does not meet the specific criteria of induction for acute leukemia or myeloablative therapy is a frequent audit trigger.
- Failing to differentiate between the induction phase and maintenance phase leads to incorrect use of G390 when G075 or G382 would be the appropriate management codes.
Billing Tips
- Ensure the clinical note explicitly mentions the 'initial dosing phase' and 'cytokine release syndrome' risk when billing for bispecific antibodies to justify the use of G390 over standard infusion supervision codes.
Effective: April 1, 2025
J. Diagnostic and Therapeutic Procedures
DIAGNOSTIC AND THERAPEUTIC PROCEDURES
ManagementFee
Diagnostic and Therapeutic Procedures
The medical record must document the supervision of chemotherapy for the induction phase of acute leukemia or myeloablative therapy prior to bone marrow transplantation to support the claim, as per general medical record requirements outlined in .
maximum of 1 per induction phase or myeloablative therapy
maximum of 1 per infusion (for biologic agent(s) such as Chimeric Antigen Receptor T-Cell Therapy (CAR-T) infusion)
maximum of 3 per initial dosing phase (for bispecific antibody infusion, where there is a high risk of cytokine release syndrome)
Ready to bill this code?
SnapBill makes OHIP billing simple — auto-filled codes, validation, and batch submission.